Search This Blog

Monday, April 13, 2026

Allogene's cemacabtagene ansegedleucel hits 58.3% MRD negativity vs 16.7% in Phase 2

 

Allogene's cemacabtagene ansegedleucel hits 58.3% MRD negativity vs 16.7% in Phase 2 ALPHA3 LBCL interim readout

  • Interim futility analysis from pivotal Phase 2 ALPHA3 trial conducted in first-line consolidation large B-cell lymphoma (LBCL).
  • Cemacabtagene ansegedleucel showed a favorable safety profile compared with observation arm in first-line consolidation LBCL.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)